Antagonism of IAPs enhances CAR T-cell efficacy
Details
Publication Year 2019-02, Volume 7, Issue #2, Page 183-192
Journal Title
Cancer Immunol Research
Publication Type
Journal Article
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has proven successful in the treatment of hematological malignancies, notably acute lymphoblastic leukemia and B-cell lymphoma. However, the efficacy of CAR T cells against solid tumors is poor, likely due to tumor-associated immunosuppression. Here, we demonstrated that antagonizing the "inhibitor of apoptosis proteins" with the clinical smac-mimetic, birinapant, significantly enhanced the antitumor activity of CAR T cells in a tumor necrosis factor (TNF)-dependent manner. Enhanced tumor cell death occurred independently of the perforin-mediated granule exocytosis pathway, underscoring the cytotoxic potential of CAR T-cell-derived TNF. Combining CAR T-cell therapy with birinapant significantly reduced established tumor growth in vivo, where either therapy alone was relatively ineffective. Using patient biopsy-derived tumoroids, we demonstrated the synergistic potential of combining CAR T-cell therapy with smac-mimetics. Taken together, we identified CAR T-cell-derived TNF as a potent antitumor effector, which can be further harnessed by smac-mimetics.
Publisher
AACR
WEHI Research Division(s)
Inflammation
PubMed ID
30651288
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2019-03-13 08:04:18
Last Modified: 2019-03-13 09:18:54
An error has occurred. This application may no longer respond until reloaded. Reload 🗙